Clinical Research Directory

Inclusion Criteria: * Breast cancer patients aged 20 years or older with clinical stage IIA or higher on imaging studies * Patients with triple-negative breast cancer confirmed on tissue biopsy * Cold immune tumor environment with tumor-infiltrating lymphocytes (TILs) \<30% and PD-L1 Combined Positive Score (CPS) \<10 on immunohistochemical staining of biopsy specimens * Patients with no prior history of breast cancer * Patients with no prior history of chemotherapy or radiation therapy * Patients scheduled to receive partial breast irradiation * Patients with ECOG performance status of 0-2 * Patients who voluntarily signed the informed consent form for study participation Exclusion Criteria: * Patients with non-triple-negative breast cancer on tissue biopsy * Patients scheduled for surgery without neoadjuvant chemotherapy * Patients with TILs ≥30% or PD-L1 CPS ≥10 on immunohistochemical staining of biopsy specimens (immune-hot tumor) * Patients with recurrent breast cancer or de novo stage IV disease * Patients who have previously received chemotherapy and/or radiation therapy to the ipsilateral breast and chest prior to study participation * Patients unable to receive neoadjuvant chemotherapy and Pembrolizumab * Vulnerable research subjects who are unable to participate voluntarily in the study due to physical/mental disabilities